{"url_path":"/sec/fdmt/8-k/2026-06-29/item-2-03","section_key":"item-2-03","section_title":"Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1650648/0001193125-26-286880-index.html","accession_number":"0001193125-26-286880","cik":"0001650648","ticker":"FDMT","issuer_name":"4D Molecular Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1650648/0001193125-26-286880-index.html","primary_entity_key":"0001650648","primary_entity_name":"4D Molecular Therapeutics, Inc."},"word_count":89,"has_tables":true,"body_markdown":"Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant\n\nThe information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\n \n4D MOLECULAR THERAPEUTICS, INC.\n\nDate: June 29, 2026\n \n\n \nBy:\n \n\n/s/ Kristian Humer\n\n \n\n \n\n \nKristian Humer\nChief Financial Officer"}